INVO Bioscience Receives Nasdaq Delisting Notice Over Late Filings

INVO Bioscience received a delisting determination notice from the Nasdaq Stock Market on June 2, 2026. The notice cited the company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. This action places the fertility-focused medical device company’s listing status in immediate jeopardy. INVO stock closed its last trading session at $0.47, down approximately 65% year-to-date.

Context — [why this matters now]

Nasdaq Listing Rule 5250(c)(1) requires timely filing of all required periodic financial reports. The exchange’s crackdown on non-compliant issuers has intensified in 2026 following broader SEC scrutiny of financial disclosure timelines. For developmental-stage healthcare companies like INVO Bioscience, maintaining a Nasdaq listing is critical for accessing public capital markets and sustaining investor credibility.

The current macro backdrop features elevated interest rates, which have pressured speculative biotech equities and tightened funding channels. The SPDR S&P Biotech ETF (XBI) is down 12% year-to-date, reflecting a risk-off sentiment in the sector. This environment makes regulatory compliance more urgent for small-cap issuers reliant on equity financing.

INVO’s specific catalyst was the missed May 15, 2026, deadline for its first-quarter filing. The company attributed the delay to complexities in finalizing its financial statements. This follows a pattern; INVO received a prior delinquency notice in November 2025 for a late 10-Q filing.

Data — [what the numbers show]

INVO Bioscience’s market capitalization stands at approximately $2.1 million, based on 4.5 million shares outstanding. The stock’s precipitous decline represents a loss of over $4 million in market value since January 2026. The company’s last reported cash and equivalents balance was $1.7 million as of December 31, 2025.

The notice triggers an immediate suspension of trading, pending an appeal. INVO must request a hearing by June 9, 2026, to avoid formal delisting. This provides a brief seven-day window for the company to act. The appeal process typically stays any suspension action for up to 15 days.

Comparatively, over 30 companies received similar delisting warnings from Nasdaq in the first quarter of 2026 for filing delinquencies. The average appeal success rate for such cases historically sits near 40%, though outcomes are highly fact-specific. Delisted equities often migrate to the OTC Pink Sheets, where average daily volume can decline by over 80%.

Analysis — [what it means for markets / sectors / tickers]

The direct impact is confined to INVO Bioscience shareholders, who face increased illiquidity and potential permanent capital impairment. The development signals to the micro-cap biotech sector that Nasdaq is enforcing listing standards rigorously, which may pressure other delinquent filers like similar-sized peers in the medical technology space.

A counter-argument exists that delisting is a procedural consequence, not necessarily a reflection of the underlying business viability. INVO’s flagship INVOcell device holds FDA clearance and represents a novel approach to fertility treatment. The company could theoretically continue operations as a private entity or on an OTC market.

The primary risk is that a delisting severs access to the institutional capital required to fund commercial operations and clinical development. Existing investors, primarily retail, are likely trapped in positions with limited exit options. Short interest is negligible, indicating no significant speculative positioning against the stock ahead of the news.

Outlook — [what to watch next]

The immediate catalyst is INVO’s decision to appeal by the June 9, 2026, deadline. A hearing before a Nasdaq Panel will likely be scheduled within the following four weeks. The panel’s decision will be the definitive event for the listing status.

Investors should monitor any filing of the delinquent 10-Q form with the SEC, as a timely filing could form the basis of a successful appeal. The company’s cash burn rate, last reported at roughly $0.5 million per quarter, is another critical level to watch for going concern disclosures.

Should delisting occur, key support levels for the stock on the OTC market are largely indeterminable due to expected low liquidity. The broader XBI ETF will be largely unaffected by this specific event, but it remains a barometer for risk sentiment in the biotech sector.

Frequently Asked Questions

What happens to my shares if INVO is delisted from Nasdaq?

If delisted, INVO Bioscience stock would likely begin trading on the OTC Pink Sheets market. This over-the-counter venue has significantly lower liquidity and visibility than Nasdaq. Trading may become more difficult, with wider bid-ask spreads, and some brokerage platforms may restrict transactions in the security.

How does this INVO delisting notice compare to other biotech companies?

Delisting due to filing delays is not uncommon among small-cap biotechnology firms. In 2025, Novaccess Global Inc. received a similar notice and was subsequently delisted. The common factor is typically a constrained resource base, where limited capital is prioritized for R&D over administrative compliance, creating a recurring vulnerability.

Can INVO Bioscience recover from a potential delisting?

Recovery is challenging but possible. It would require the company to successfully file all delinquent reports, demonstrate compliance with all other Nasdaq metrics, and reapply for listing. This process can take over a year. The more probable path is an acquisition of its technology assets by a larger, well-capitalized medical device company.

Bottom Line

INVO Bioscience’s Nasdaq listing is at severe risk following a second filing delinquency.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.